Deucravacitinib
Sign in to save this workspacePrimary targets: TYK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
98.99
Gini
0.718
CATDS
0.030
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Deucravacitinib. Strongest target: C_MET at 97.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | C_MET | 97.9% | 2.1% |
| 2 | FGFR3 | 93.3% | 6.7% |
| 3 | FGFR2 | 92.5% | 7.5% |
| 4 | FGFR4 | 92.0% | 8.0% |
| 5 | FGFR1 | 85.1% | 14.9% |
| 6 | EIF2AK2 | 83.2% | 16.8% |
| 7 | GSK3B | 75.0% | 25.0% |
| 8 | FLT4_VEGFR3 | 66.8% | 33.2% |
| 9 | HPK1_MAP4K1 | 64.0% | 36.0% |
| 10 | FLT1_VEGFR1 | 61.9% | 38.1% |
| 11 | BMPR2 | 60.8% | 39.2% |
| 12 | LCK | 56.7% | 43.3% |
| 13 | LYN | 49.8% | 50.2% |
| 14 | TNIK | 49.1% | 50.9% |
| 15 | FMS | 46.0% | 54.0% |
| 16 | RET | 45.5% | 54.5% |
| 17 | C_KIT | 45.4% | 54.6% |
| 18 | DDR1 | 44.8% | 55.2% |
| 19 | TYRO3_SKY | 42.0% | 58.0% |
| 20 | ABL1 | 39.7% | 60.3% |
Selectivity landscape
Where Deucravacitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Deucravacitinib.
Atlas insights for Deucravacitinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target1%
Off-target99%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1979.91 | |
| ALLOGRAFT_REJECTION | 4683.79 | |
| ANDROGEN_RESPONSE | 1576.79 | |
| ANGIOGENESIS | 734.46 | |
| APICAL_JUNCTION | 5012.52 | |
| APICAL_SURFACE | 508.63 | |
| APOPTOSIS | 5213.49 | |
| BILE_ACID_METABOLISM | 398.49 | |
| CHOLESTEROL_HOMEOSTASIS | 754.78 | |
| COAGULATION | 548.07 | |
| COMPLEMENT | 2661.22 | |
| DNA_REPAIR | 1723.69 | |
| E2F_TARGETS | 4030.63 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1471.82 | |
| ESTROGEN_RESPONSE_EARLY | 2287.36 | |
| ESTROGEN_RESPONSE_LATE | 2440.88 | |
| FATTY_ACID_METABOLISM | 526.63 | |
| G2M_CHECKPOINT | 4626.88 | |
| GLYCOLYSIS | 1878.63 | |
| HEDGEHOG_SIGNALING | 494.50 | |
| HEME_METABOLISM | 1902.00 | |
| HYPOXIA | 2955.11 | |
| IL2_STAT5_SIGNALING | 2293.78 | |
| IL6_JAK_STAT3_SIGNALING | 3316.43 | |
| INFLAMMATORY_RESPONSE | 2688.86 | |
| INTERFERON_ALPHA_RESPONSE | 571.12 | |
| INTERFERON_GAMMA_RESPONSE | 4121.87 | |
| KRAS_SIGNALING_DN | 608.18 | |
| KRAS_SIGNALING_UP | 1987.70 | |
| MITOTIC_SPINDLE | 4381.39 | |
| MTORC1_SIGNALING | 2574.21 | |
| MYC_TARGETS_V1 | 2984.89 | |
| MYC_TARGETS_V2 | 711.92 | |
| MYOGENESIS | 2194.46 | |
| NOTCH_SIGNALING | 265.11 | |
| OXIDATIVE_PHOSPHORYLATION | 945.90 | |
| P53_PATHWAY | 3075.42 | |
| PANCREAS_BETA_CELLS | 498.99 | |
| PEROXISOME | 967.62 | |
| PI3K_AKT_MTOR_SIGNALING | 5959.27 | |
| PROTEIN_SECRETION | 1240.64 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 492.51 | |
| SPERMATOGENESIS | 1103.60 | |
| TGF_BETA_SIGNALING | 1849.73 | |
| TNFA_SIGNALING_VIA_NFKB | 3629.28 | |
| UNFOLDED_PROTEIN_RESPONSE | 1018.58 | |
| UV_RESPONSE_DN | 3500.10 | |
| UV_RESPONSE_UP | 2216.59 | |
| WNT_BETA_CATENIN_SIGNALING | 1407.85 | |
| XENOBIOTIC_METABOLISM | 1245.63 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.865 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.845 |
| SRR12202498 | — | 0.843 |
| SRR23303752 | — | 0.841 |
| aMVAC.P_005_TURBT_S223 | — | 0.839 |
Annotations
Sign in to read and post annotations.
Loading…